Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer

Cancer Letters

Volumn 372, Issue 2, 2016, Pages 187-191

  Roviello, Giandomenico ^a,b   Ravelli, Andrea ^b,c   Polom, Karol ^d   Petrioli, Roberto ^d   Marano, Luigi ^e   Marrelli, Daniele ^d   Roviello, Franco ^d   Generali, Daniele ^b,f  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CREMONA HOSPITAL   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

^d UNIVERSITY OF SIENA   (Italy)

^e Ospedale San Matteo degli Infermi   (Italy)

^f UNIVERSITY OF TRIESTE   (Italy)

Author keywords

Apatinib; Gastric cancer; VEGFR2

Indexed keywords

APATINIB; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2; ANGIOGENESIS INHIBITOR; PROTEIN KINASE INHIBITOR; PYRIDINE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2, HUMAN;

ADVANCED CANCER; ANGIOGENESIS; DRUG TARGETING; HUMAN; META ANALYSIS (TOPIC); METASTASIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; SHORT SURVEY; STOMACH CANCER; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANIMALS; HUMANS; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRIDINES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84957611154     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.01.014     Document Type: Review

References (43)

1. Torre L.A., et al. Global cancer statistics, 2012. CA Cancer J. Clin 2015, 65(2):87-108.
2. Wagner A.D., et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst. Rev 2010, (3). CD004064.
3. Petrioli R., et al. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience. Cancer Chemother. Pharmacol 2015, 75(5):941-947.
4. Lordick F., et al. Unmet needs and challenges in gastric cancer: the way forward. Cancer Treat. Rev 2014, 40(6):692-700.
5. Bang Y.J., et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376(9742):687-697.
6. de Mello R.A., Marques A.M., Araujo A. HER2 therapies and gastric cancer: a step forward. World J. Gastroenterol 2013, 19(37):6165-6169.
7. Janjigian Y.Y., et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann. Oncol 2012, 23(10):2656-2662.
8. Fuchs C.S., et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2014, 383(9911):31-39.
9. Wilke H., et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014, 15(11):1224-1235.
10. Roviello G., et al. Angiogenesis inhibitors in gastric and gastroesophageal junction cancer. Gastric Cancer 2016, 19(1):31-41.
11. Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014, 513(7517):202-209.
12. Tian S., et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci 2011, 102(7):1374-1380.
13. Wilhelm S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64(19):7099-7109.
14. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med 2003, 9(6):669-676.
15. Longo R., Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother. Pharmacol 2007, 60(2):151-170.
16. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol 2005, 23(5):1011-1027.
17. Holmes K., et al. Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. Cell. Signal 2007, 19(10):2003-2012.
18. Ebos J.M., et al. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res 2004, 2(6):315-326.
19. Chen P., Iruela-Arispe I., Lou L., Sun P., Yuan K. VEGFr inhibitor YN968D1 xenograft dose response studies against human colon cancer Ls174t and HT29. Proc. Am. Assoc. Cancer Res 2006, 47. Abstract 1764.
20. Mendel D.B., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res 2003, 9(1):327-337.
21. Li J., et al. Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies. BMC Cancer 2010, 10:529.
22. Li J., et al. A randomized, double-blind, multicenter, phase II, three-arm, placebo-control study of apatinib as third-line treatment in patients with metastatic gastric carcinoma. J. Clin. Oncol 2011, 29(Suppl.). Abstract 4019.
23. Li J., et al. Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial. J. Clin. Oncol 2013, 31(26):3219-3225.
24. Qin S., et al. Phase III study of apatinib in advanced gastric cancer: a randomized, double-blind, placebo-controlled trial. J. Clin. Oncol 2014, 32(5s). Suppl; abstr 4003.
25. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med 1995, 1(1):27-31.
26. Tanigawa N., et al. Correlation between expression of vascular endothelial growth factor and tumor vascularity, and patient outcome in human gastric carcinoma. J. Clin. Oncol 1997, 15(2):826-832.
27. Aprile G., et al. Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: a critical insight. Crit. Rev. Oncol. Hematol 2015, 95(2):165-178.
28. Fontana E., Sclafani F., Cunningham D. Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian J. Med. Paediatr. Oncol 2014, 35(4):253-262.
29. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9(Suppl. 1):2-10.
30. Glade-Bender J., Kandel J.J., Yamashiro D.J. VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther 2003, 3(2):263-276.
31. Takahashi Y., et al. Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin. Cancer Res 1996, 2(10):1679-1684.
32. Hawkes E., et al. Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer. Eur. J. Cancer 2011, 47(8):1146-1151.
33. Park S.H., et al. Mitomycin C plus S-1 as second-line therapy in patients with advanced gastric cancer: a noncomparative phase II study. Anticancer Drugs 2008, 19(3):303-307.
34. Rini B.I., Wilding G., Hudes G., Stadler W.M., Kim S., Tarazi J., et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. J. Clin. Oncol 2009, 27(27):4462-4468.
35. Apperley J.F., Cortes J.E., Kim D.W., Roy L., Roboz G.J., Rosti G., et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J. Clin. Oncol 2009, 27(21):3472-3479.
36. Deng N., et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 2012, 61(5):673-684.
37. Okines A.F., et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial. J. Clin. Oncol 2010, 28(25):3945-3950.
38. Rao S., et al. Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer. Br. J. Cancer 2008, 99(6):868-874.
39. Rojo F., et al. Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma. J. Clin. Oncol 2006, 24(26):4309-4316.
40. Dragovich T., et al. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127. J. Clin. Oncol 2006, 24(30):4922-4927.
41. Doi T., et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J. Clin. Oncol 2010, 28(11):1904-1910.
42. Marano L., et al. c-Met targeting in advanced gastric cancer: an open challenge. Cancer Lett 2015, 365(1):30-36.
43. Ciliberto D., et al. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: evidence does not translate?. Cancer Biol. Ther 2015, 16(8):1148-1159.